

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14

**Final Minutes  
Toxicology Subcommittee of the  
Scientific Advisory Committee  
July 13, 2020  
Department of Forensic Science, Held Electronically**

15  
16

**Subcommittee Members Present**

17  
18  
19  
20  
21  
22  
23  
24  
25

Maureen C. Bottrell  
Leslie E. Edinboro, Ph.D., *Chair*  
Barry S. Levine, Ph.D.  
Richard P. Meyers  
Jami St. Clair

26  
27

**Staff Members Present**

28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

David A. Barron, Ph.D., Deputy Director  
Katya N. Herndon, Chief Deputy Director  
James W. Hutchings, Ph.D., Toxicology Program Manager  
Linda C. Jackson, Director  
Amy M. Jenkins, Department Counsel  
Alka B. Lohmann, Director of Technical Services  
Jennifer L. Taylor, Procurement Specialist I, *Secretary*  
Rebecca Wagner, Ph.D., Research Section Supervisor

39  
40

**Call to Order by Subcommittee Chair**

41  
42  
43  
44  
45  
46

As a result of the state of emergency declared by Governor Northam due to COVID-19, the Toxicology Subcommittee conducted the meeting by electronic communication means using the Google Meet platform. The public was permitted to attend and participate via video or audio conference. Directions for public participation were provided on the meeting agenda and posted on Virginia's Town Hall.

Dr. Edinboro called the meeting of the Toxicology Subcommittee ("Subcommittee") to order at 3:00 p.m. Dr. Edinboro requested Ms. Taylor to call the roll to ensure that a quorum was present. All Subcommittee members were in attendance, and Ms. Taylor advised that a quorum was present.

**Adoption of Agenda**

Dr. Edinboro advised that the first order of business was the adoption of the draft agenda for the meeting. Dr. Edinboro noted that everyone should have received a copy in advance and asked for a motion to adopt the agenda. Ms. St. Clair made a motion to adopt the agenda, which was seconded by Dr. Levine. A roll-call vote was taken, and the Subcommittee members voted as follows:

47 Ms. Bottrell – Yes  
48 Dr. Edinboro – Yes  
49 Dr. Levine – Yes  
50 Mr. Meyers – Yes  
51 Ms. St. Clair – Yes

52

53 **Approval of Draft Minutes from May 7, 2019 Meeting**

54

55 Dr. Edinboro asked if there were any proposed changes to the draft minutes from the May 7, 2019  
56 meeting of the Toxicology Subcommittee. Being none, Mr. Meyers made a motion to adopt the  
57 minutes, which was seconded by Ms. Bottrell. A roll-call vote was taken, and the Subcommittee  
58 members voted as follows:

59

60 Ms. Bottrell – Yes  
61 Dr. Edinboro – Yes  
62 Dr. Levine – Yes  
63 Mr. Meyers – Yes  
64 Ms. St. Clair – Yes

65

66 **Discussion of Method Validation/Verification Documentation**

67

68 In advance of the meeting, the members of the Subcommittee were provided copies of  
69 validation/verification documentation for the following methods:

70

71 • Non-steroidal anti-inflammatory drugs (NSAIDs) by Liquid Chromatography Tandem  
72 Mass Spectrometry (LCMSMS) – The validation summary for the quantitative analysis  
73 of NSAIDs in biological specimens by LCMSMS. This validation includes the  
74 evaluation of two different working ranges.

75 • Gamma-hydroxybutyrate (GHB) by LCMSMS – The validation summary for the  
76 quantitative analysis of GHB, gamma-butyrolactone (GBL), and 1,4-butanediol in  
77 biological specimens by LCMSMS. This validation includes the evaluation of blood  
78 and urine matrices for the calibration curve and quality control samples.

79 • Automated Liquid Handling System (Hamilton) Verification Plan – The plan to verify  
80 the performance of the Hamilton STAR automated liquid handling system based on the  
81 previously validated manual solid phase extraction and quantitation of opioids and  
82 cocaine in biological matrices by tandem mass spectrometry.

83 • Automated Liquid Handling System (Hamilton) Verification Summary – The summary  
84 of the verification of the Hamilton STAR automated liquid handling system based on  
85 the Automated Liquid Handling System (Hamilton) Verification Plan.

86 • Fentanyl Derivative Quantitation by LCMSMS – The validation plan for the solid  
87 phase extraction (SPE) and quantitation of fentanyl derivatives in biological matrices  
88 by LCMSMS.

89 • Fentanyl Derivatives Qualitative Analysis by LCMSMS – The validation plan for the  
90 SPE and qualitative analysis of fentanyl derivatives in biological matrices by  
91 LCMSMS. The method was validated to adapt the current fentanyl derivatives  
92 qualitative analysis method to SPE for use on the Hamilton STAR system.

93  
94 Dr. Wagner provided an overview of each method. The Subcommittee members provided  
95 comments and asked questions, which Dr. Wagner and Dr. Hutchings answered.  
96

97 Ms. Bottrell made a motion to adopt a recommendation to have the Department experimentally  
98 determine the limit of detection of each compound present versus using an administratively  
99 determined limit of detection concentration. The motion was seconded by Mr. Myers. Dr. Levine  
100 indicated that he felt what the Department had done was acceptable and did not think it was  
101 necessary for DFS to experimentally determine the limit of detections as was being recommended.  
102 A roll-call vote on the motion was taken, and the Subcommittee members voted as follows:

103  
104 Ms. Bottrell – Yes  
105 Dr. Edinboro – Yes  
106 Dr. Levine – No  
107 Mr. Meyers – Yes  
108 Ms. St. Clair – Yes  
109

110 The recommendation was adopted. Dr. Levine then made a motion to close the review, which was  
111 seconded by Ms. Bottrell. A roll-call vote was taken, and the Subcommittee members voted as  
112 follows:

113  
114 Ms. Bottrell – Yes  
115 Dr. Edinboro – Yes  
116 Dr. Levine – Yes  
117 Mr. Meyers – Yes  
118 Ms. St. Clair – Yes  
119

## 120 **Discussion of Methods in Development**

121  
122 Dr. Hutchings provided the Subcommittee with an overview of the following four methods in  
123 development:

- 124
- 125 • Barbiturates Quantitation by LCMSMS – This method would replace the current  
126 methodology that requires 1.0 mL of biological matrices and analysis using gas  
127 chromatography mass spectrometry (GC-MS).
  - 128 • Cannabinoids Extraction by Automated Liquid Handling System – This method is  
129 dependent upon grant funding to explore a variety of extraction techniques and  
130 instrumental conditions to achieve the best methodology while simultaneously  
131 expanding cannabinoid testing capabilities.
  - 132 • Miscellaneous Basic Drug Quantitation by LCMSMS – This method would replace  
133 current methodology using GC-MS. This method would combine several methods into  
134 one.
  - 135 • Flualprazolam Quantitation by LCMSMS – This method would add flualprazolam to  
136 the currently validated benzodiazepine LCMSMS method.

137

138 The Subcommittee members provided comments and asked questions about the methods in  
139 development, which Dr. Hutchings and Dr. Wagner answered. Mr. Meyers made a motion that the  
140 review of the methods in development be closed, which was seconded by Dr. Levine. A roll-call  
141 vote was taken, and the Subcommittee members voted as follows:

142  
143 Ms. Bottrell – Yes  
144 Dr. Edinboro – Yes  
145 Dr. Levine – Yes  
146 Mr. Meyers – Yes  
147 Ms. St. Clair – Yes

148  
149 **Public Comment**

150  
151 Dr. Edinboro inquired whether any member of the public would like to provide any comment. No  
152 member of the public was in attendance.

153  
154 **Adjournment**

155  
156 Ms. St. Clair moved that the meeting of the Subcommittee be adjourned, which was seconded by  
157 Mr. Meyers, and passed by unanimous vote. A roll-call vote was taken, and the Subcommittee  
158 members voted as follows:

159  
160 Ms. Bottrell – Yes  
161 Dr. Edinboro – Yes  
162 Dr. Levine – Yes  
163 Mr. Meyers – Yes  
164 Ms. St. Clair – Yes

165  
166 The meeting adjourned at 3:58 p.m.